TSHA at a glance
Taysha Gene Therapies, Inc. (TSHA, SEC CIK 1806310) filed its latest 10-K annual report on March 19, 2026, a 10-Q quarterly report on August 11, 2026, an 8-K current report on August 11, 2026 and Form 4 insider filings as recently as July 10, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Taysha Gene Therapies, Inc. (TSHA) reported revenue of $9.8 million (up 17.3% from FY2024) and a net loss of $109.0 million. Diluted EPS was -$0.34.
- As of June 30, 2026, 28 institutional investment managers tracked by SignalX reported holding Taysha Gene Therapies, Inc. (TSHA) shares worth $787.7 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Nagendran Sukumar on July 10, 2026 of 200,000 shares at $6.24 per share.
- In the last 90 days, TSHA insiders reported 0 open-market purchases ($0) and 1 open-market sale ($1.2M) on Form 4, a net sale of $1.2M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $9.8M
- +17.3% vs prior year
- Insiders · 90 days
- 0 buys · 1 sell
- Net −$1.2M
- 13F holders
- 28 funds
- $787.7M · +0 vs prior quarter
- Latest 8-K
- Aug 11, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Product revenue $0; no approved products or product-sale revenue
- Net loss $89.0M for six months ended June 30, 2026; accumulated deficit $800.3M
- REVEAL pivotal trial: 17 patients dosed; topline interim data expected first half 2027
- Cash deployment: $3.0M investing outflow for Abeona milestone payment
- Ongoing headwinds: significant expenses and operating losses expected as clinical and manufacturing activities expand
Risk Factors
- No risk-factors section provided in the submitted text
- No newly added risk trigger identifiable from the submitted text
- No regulatory, legal, compliance, operational, competitive, market, or financial risks disclosed in the submitted text
AI summary of the TSHA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Item 2.02 furnished an 8-K and Exhibit 99.1, but the provided text contains no earnings figures or reporting-period results
- Information is not deemed filed under Exchange Act Section 18, limiting associated liability and incorporation by referenceWinvalid
Item EX-99.1: Item EX-99.1
- REVEAL pivotal dosing completed at 17 patients; six-month interim data and FDA BLA-pathway feedback expected in 1H 2027
- TSHA-102 safety remains favorable across 33 treated patients, with no severe treatment-related SAEs or DLTs as of August 2026
Item 8.01: Other Events
- Public offering commenced and priced June 24, 2026, indicating immediate capital raising and potential shareholder dilution
- Net proceeds plus existing cash expected to fund operating expenses and capital expenditures into the second half of 2028
Item 1.01: Entry into a Material Definitive Agreement
- Public offering of 32.5M shares plus pre-funded warrants for 833,333 shares at $6.00 per share
- Gross proceeds imply approximately $195.0M before discounts and expenses
Item EX-99.1: Item EX-99.1
- Proposed $200.0 million underwritten offering of common stock and pre-funded warrants
- Potential dilution for existing shareholders from newly issued shares and warrant exercises
Item 7.01: Regulation FD Disclosure
- Exhibit 99.1 furnished under Regulation FD, with disclosure not deemed filed under Exchange Act Section 18
- Liability protections limit use in other SEC filings unless expressly incorporated by reference
Item 8.01: Other Events
- Presentation covers clinical and regulatory updates for TSHA-102
- Exhibit 99.2 contains the materials, providing investors detail beyond the brief 8-K disclosure
Item EX-99.1: Item EX-99.1
- REVEAL pivotal trial dosing completed in 17 patients, advancing TSHA-102 toward a 6-month interim efficacy analysis
- FDA-aligned efficacy threshold is 33% responders versus a 6.7% natural-history null hypothesis
AI summaries of TSHA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for TSHA
Don't miss the next TSHA filing
- Alerts as it files. A push when TSHA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut TSHA, by share count.
- Ask anything. An AI agent that reads every TSHA filing and answers with sources.
TSHA alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Nagendran Sukumar | Sell | Jul 10, 2026 | 200,000 | $6.24 |
| Donenberg Phillip B. | A | Jun 1, 2026 | 42,671 | - |
| Long Alison S | A | Jun 1, 2026 | 21,335 | - |
| Long Alison S | A | Jun 1, 2026 | 42,671 | - |
| Sepp-Lorenzino Laura | A | Jun 1, 2026 | 21,335 | - |
| Stalfort John A III | A | Jun 1, 2026 | 21,335 | - |
| Stalfort John A III | A | Jun 1, 2026 | 42,671 | - |
| Sepp-Lorenzino Laura | A | Jun 1, 2026 | 42,671 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $8.3M | $9.8M |
| Operating Income | -$72.4M | -$91.5M | -$110.5M |
| Net Income | -$111.6M | -$89.3M | -$109.0M |
| Op. Margin | - | -1097.6% | -1130.6% |
| Net Margin | - | -1071.6% | -1115.3% |
| Balance Sheet | |||
| Total Assets | - | $160.4M | $343.3M |
| Equity | - | $71.5M | $246.9M |
| ROE | - | -124.8% | -44.1% |
| Per Share | |||
| EPS | - | $-0.36 | $-0.34 |
| Cash Flow | |||
| Operating CF | -$73.0M | -$81.2M | -$93.1M |
| CapEx | $3.9M | $374K | $738K |
Source: XBRL data in Taysha Gene Therapies, Inc. (TSHA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate TSHA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 28 | $787.7M |
| Q1 2026 | 28 | $501.4M |
| Q4 2025 | 27 | $572.5M |
| Q3 2025 | 26 | $319.3M |
| Q2 2025 | 28 | $190.8M |
| Q1 2025 | 22 | $71.7M |
| Q4 2024 | 19 | $62.9M |
| Q3 2024 | 14 | $18.2M |
- BlackRock+2.33M (+13%)
- Vanguard Capital Management LLC+2.25M (+22%)
- Citadel Advisors LLC+1.12M (+273%)
- Vanguard Portfolio Management LLC+1.12M (+55%)
- Northern Trust+411.9K (+23%)
- Morgan Stanley−1.48M (-8%)
- Millennium Management−1.15M (-35%)
- FMR LLC (Fidelity)−984.8K (-7%)
- Two Sigma Investments−507.4K (-68%)
- Bank of America Corp−304.2K (-18%)
- Allstate+19.4K
- Renaissance Technologies LLC−413.2K
Source: 13F-HR filings on SEC EDGAR (aggregated from 192 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
TSHA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Aug 11, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 11, 2026 | - | Analysis | - |
| 4 | Jul 10, 2026 | - | - | - |
| 8-K | Jun 25, 2026 | - | Analysis | - |
| 8-K | Jun 22, 2026 | - | Analysis | - |
| 4 | Jun 2, 2026 | - | - | |
| 4 | Jun 2, 2026 | - | - | |
| 8-K | Jun 2, 2026 | - | Analysis | |
| 4 | Jun 2, 2026 | - | - | |
| 4 | Jun 2, 2026 | - | - | |
| 8-K | May 6, 2026 | - | Analysis | |
| 10-Q | May 6, 2026 | Mar 31, 2026 | Analysis | |
| 4 | Apr 13, 2026 | - | - | - |
| 10-K | Mar 19, 2026 | Dec 31, 2025 | - | |
| 8-K | Mar 19, 2026 | - | Analysis | - |
| SC 13G | Feb 17, 2026 | - | - | |
| 4 | Feb 6, 2026 | - | - | |
| 4 | Jan 27, 2026 | - | - | |
| 4 | Jan 27, 2026 | - | - | |
| 4 | Jan 27, 2026 | - | - | |
| 4 | Jan 14, 2026 | - | - | |
| 4 | Jan 14, 2026 | - | - | |
| 4 | Jan 14, 2026 | - | - | |
| 4 | Dec 1, 2025 | - | - | |
| 10-Q | Nov 4, 2025 | Sep 30, 2025 | Analysis |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
TSHA SEC filings: frequently asked questions
Are TSHA insiders buying or selling?
In the last 90 days, Taysha Gene Therapies, Inc. (TSHA) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $1.2 million by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold TSHA stock?
As of June 30, 2026, the largest Taysha Gene Therapies, Inc. (TSHA) holders among the 13F filers tracked by SignalX were Goldman Sachs Group ($154.7 million), BlackRock ($140.9 million), Morgan Stanley ($112.3 million), FMR LLC (Fidelity) ($90.8 million), Vanguard Capital Management LLC ($85.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was TSHA's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Taysha Gene Therapies, Inc. (TSHA) reported revenue of $9.8 million (up 17.3% from FY2024) and a net loss of $109.0 million. Diluted EPS was -$0.34. The figures come from the XBRL data in the 10-K.
What did TSHA report in its latest 8-K?
Taysha Gene Therapies, Inc. (TSHA) filed an 8-K on August 11, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Item 2.02 furnished an 8-K and Exhibit 99.1, but the provided text contains no earnings figures or reporting-period results.
What are the latest TSHA SEC filings?
Taysha Gene Therapies, Inc. (TSHA) filed its latest 10-K annual report on March 19, 2026, a 10-Q quarterly report on August 11, 2026, an 8-K current report on August 11, 2026 and a Form 4 insider filing on July 10, 2026.
What is TSHA's SEC CIK number?
Taysha Gene Therapies, Inc. (TSHA)'s SEC Central Index Key (CIK) is 1806310. EDGAR lists every TSHA filing under that number.
Ask anything about TSHA
The research agent reads TSHA's filings, financials, insider trades and 13F holders, then answers with sources.